Novartis (NVS) return on equity (ROE)

Return on equity · fiscal 2025
30.3%

Novartis (NVS) earned a return on equity of 30.3% in fiscal 2025 (the year ended December 31, 2025). That is 3.2 percentage points higher than the 27.1% of fiscal 2024. Figures as of 17 Nov 2026, 23:39 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
30.3%
Change on fiscal 2024
+3.2 pts
Highest on record
31.8%fiscal 2023
Lowest on record
11.7%fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Novartis return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was 31.8% in fiscal 2023 and the lowest 11.7% in fiscal 2022. The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 27.1%.

History · 4 fiscal years

Return on equity by fiscal year

Novartis return on equity (ROE), year by year

Novartis (NVS) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202530.3% 3.2 pts up
202427.1% 4.7 pts down
202331.8% 20.1 pts up
202211.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Novartis and comparable companies
CompanyReturn on equityFiscal year
AbbVie ABBV128.7%2024
Merck & Co MRK34.7%2025
UnitedHealth Group UNH12.8%2025
Novartis NVS30.3%2025
AstraZeneca AZN21.0%2025
Thermo Fisher Scientific TMO12.6%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NVS

Novartis, figure by figure

Novartis (NVS) overview: price, valuation and scorecardAll health care companies by market value

Novartis return on equity (ROE): questions and answers

What is Novartis's return on equity?

Novartis (NVS) earned a return on equity of 30.3% in fiscal 2025 (the year ended December 31, 2025). That is 3.2 percentage points higher than the 27.1% of fiscal 2024.

Is Novartis's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 67% of the 3 earlier fiscal years on record, whose median is 27.1%.

What are the highest and lowest return on equity figures on record for Novartis?

Across the 4 fiscal years on record (2022–2025), the highest was 31.8% in fiscal 2023 and the lowest 11.7% in fiscal 2022.

How is Novartis's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Novartis (NVS) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/NVS/roe

Underlying data: Yahoo Finance.